Table 2.

Summary statistics for maraviroc pharmacokinetic parameters by treatment group

Treatment	Tmax (h)*	Cmax (ng ml−1)†	AUC12(ng h ml−1)†	CLR (l h−1)*
Cohort 1: maraviroc + efavirenz/lamivudine/zidovudine	2.1 (0.8)	389 (45%)	1060 (39%)	12.0 (3.6)
Cohort 2: maraviroc + efavirenz/didanosine/tenofovir	1.9 (0.4)	447 (89%)	1090 (85%)	8.2 (2.5)
Cohort 3: maraviroc + nevirapine/lamivudine/tenofovir	2.0 (0.0)	900 (68%)	2270 (51%)	9.7 (3.2)
Cohort 4: maraviroc + lopinavir/ritonavir/stavudine/lamivudine	2.2 (1.1)	1050 (48%)	5990 (30%)	13.2 (4.7)
Historical control: maraviroc 300 mg	2.9 (1.2)	585 (23%)	2260 (31%)	NA

^*Arithmetic mean (SD).

^†Geometric mean (CV%).